Oral Cabotegravir + Oral Rilpivirine versus Efavirenz + 2 NRTI's

LATTE Study

Oral Cabotegravir + Oral Rilpivirine versus Efavirenz + 2 NRTI's
LATTE Study: Design

- **Background**: Phase 2b, randomized, partially blinded study done at multiple centers in the U.S. and Canada
- **Inclusion Criteria**
  - Age ≥18 years
  - Antiretroviral-naïve
  - HIV RNA >1,000 copies/mL
  - CD4 count >200 cells/mm^3
  - CrCl >50 mL/min
  - No hepatitis B
  - No significant transaminitis



Source: Margolis DA, et al. Lancet Infect Dis. 2015;15:1145-55.

Oral Cabotegravir + Oral Rilpivirine versus Efavirenz + 2 NRTI's LATTE Study: Results



*Cabotegravir data is composite of all cabotegravir doses

Source: Margolis DA, et al. Lancet Infect Dis. 2015;15:1145-55.

Oral Cabotegravir + Oral Rilpivirine versus Efavirenz + 2 NRTI's LATTE Study: Results



*During induction phase cabotegravir administered with investigator chosen 2NRTIs

Source: Margolis DA, et al. Lancet Infect Dis. 2015;15:1145-55.

National HIV Curriculum

Oral Cabotegravir + Oral Rilpivirine versus Efavirenz + 2 NRTI's LATTE Study: Conclusions

Conclusions: "Cabotegravir plus dual NRTI therapy had potent antiviral activity during the induction phase. As a two drug maintenance therapy, cabotegravir plus rilpivirine provided antiviral activity similar to efavirenz plus dual NRTIs until the end of week 96. Combined efficacy and safety results lend support to our selection of oral cabotegravir 30 mg once a day for further assessment. LATTE precedes studies of the assessment of long-acting injectable formulations of both drugs as a two-drug regimen for the treatment of HIV-1 infection."

Source: Margolis DA, et al. Lancet Infect Dis. 2015;15:1145-55.

Acknowledgments

The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $1,000,000 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.

This project is led by the University of Washington Infectious Diseases Education & Assessment (IDEA) Program.

AETC AIDS Education & Training Center Program

National HIV Curriculum

IDEA INFECTIOUS DISEASES EDUCATION & ASSESSMENT